News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Royalty Pharma AG Announces Agreement Regarding The Purchase Of The Rights To A Pre-Existing Royalty Interest In HUMIRA(R) From AstraZeneca PLC (AZN) And Cambridge Antibody Technology Group PLC  (CATG)


10/26/2006 11:18:27 AM

NEW YORK, Oct. 26 /PRNewswire/ -- Royalty Pharma announced today that it has completed the purchase of the rights to a pre-existing royalty interest in HUMIRA(R) currently held by AstraZeneca plc's subsidiary, Cambridge Antibody Technology Limited (CAT). AstraZeneca will receive US$700 million for the sale, settled in cash (subject to adjustment for all royalty amounts accrued for and received by CAT since January 1, 2006). Following this transaction, Royalty Pharma will receive royalty revenue formerly payable to CAT based on all future sales of HUMIRA(R), developed and marketed by Abbott.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO )

"Royalty Pharma is excited to partner with AstraZeneca, one of the world's leading pharmaceutical companies, in this ground-breaking royalty transaction," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "We believe that Royalty Pharma is in a unique position to collaborate with companies such as AstraZeneca to assist in optimizing the value of their strategic initiatives. We look forward to continuing to be the preeminent partner to leading research institutions, hospitals, universities, and biopharmaceutical companies. We are also pleased to expand the reach of our existing royalty portfolio, which includes leading oncology and antiviral products, to include HUMIRA(R), the fastest growing anti-TNF therapy."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property -- principally royalty interests in marketed and late stage biopharmaceutical products with a market value of over $2 billion. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products, including Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), Celgene's Thalomid(R), and now Abbott's Humira(R). The company has a ten year history of providing value to holders of royalty interests, including its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and international royalty interests in Neupogen(R) and Neulasta(R) for over $400 million. The strong market position enjoyed by the products in which Royalty Pharma owns royalties -- generally the sole or number one product in their therapeutic classes -- and its revenue diversification are some of the key attributes contributing to the investment grade rating of Royalty Pharma's finance trust, which is further wrapped by a mono-line insurer to "AAA"/"Aaa" by S&P and Moody's. More information on Royalty Pharma is available at http://www.royaltypharma.com.

Photo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comRoyalty Pharma

CONTACT: Pablo Legorreta, Chief Executive Officer, or Susannah Gray, ChiefFinancial Officer, or Alexander Kwit, General Counsel, all of RoyaltyPharma, +1-212-883-0200


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES